GlassScriptPhysician profile
David James Tang
NPI 1922006998
$28,503.12
in general payments reported to CMS, 2019-2025
25 companies · $2,054 in 2025
The $2,054 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $484 · 2021: $16K · 2022: $1,182 · 2023: $1,574 · 2024: $6,642 · 2025: $2,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,270 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,270.07 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $16,432.60 | 2020-2025 | Acuvue |
| Alcon Vision LLC | $8,734.47 | 2019-2025 | Dailies Total1, Precision 1, Air Optix Color |
| Coopervision INC. | $710.92 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Biofinity Contact Lens |
| Tarsus Pharmaceuticals, INC. | $382.41 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $336.72 | 2020-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $319.44 | 2019-2025 | Cequa |
| Allergan, INC. | $260.23 | 2019-2022 | |
| Glaukos Corporation | $208.96 | 2025 | Idosetr, Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Biotissue Holdings INC. | $191.17 | 2025 | |
| Kala Pharmaceuticals, INC. | $162.49 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $144.07 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Abbvie INC. | $113.78 | 2022-2025 | |
| Oyster Point Pharma, INC. | $81.31 | 2023-2024 | Tyrvaya |
| Harrow Eye, LLC | $63.75 | 2024-2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $57.51 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $56.37 | 2019-2020 | |
| Abb Con-Cise Optical Group LLC | $49.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.61 | 2020-2023 | |
| Thea Pharma INC. | $42.24 | 2023-2025 | Iyuzeh |
| Amgen INC. | $22.91 | 2024 | Tepezza |
| Biogen, INC. | $19.89 | 2023 | |
| Shire North American Group INC | $19.38 | 2019 | |
| Horizon Therapeutics Plc | $16.90 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $15.24 | 2019 | |
| Quidel Corporation | $15.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.